Subscribe to RSS
DOI: 10.1055/s-0029-1225288
© Georg Thieme Verlag KG Stuttgart · New York
Infektiologie und Tropenmedizin 2009
Infectiology and tropical medicine 2009Publication History
Publication Date:
10 June 2009 (online)
Was ist neu?
-
Neue Erreger: Clostridium difficile Ribotyp 027 in Deutschland angekommen.
-
Neue Viren: Boca-, Corona-, Polyoma-, Parecho- und Arenaviren.
Influenza A-Viren: zunehmende Oseltamivir-Resistenz.
-
HIV: neue Medikamente, früherer Therapiebeginn diskutiert, Prävention stagniert.
-
Tuberkulose: neue Medikamente könnten Therapiedauer verkürzen.
-
Malaria: erfolgreiche Bekämpfung, aber erste Artemisinin-Resistenzen.
-
Impfungen: Fortschritte bei der Impfstoffentwicklung gegen Malaria und Tuberkulose; neue Impfstoffe für Erwachsene in der Erprobung.
Literatur
- 1 Abdulla S, Oberholzer R, Juma O. et al . Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008; 359 2533-2544
- 2 Abedi Kiasari B, Vallely P J, Corless C E. et al . Age-related pattern of KI and WU polyomavirus infection. J Clin Virol. 2008; 43 123-125
- 3 Bejon P, Lusingu J, Olotu A. et al . Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008; 359 2521-2532
- 4 Brieu N, Guyon G, Rodière M. et al . Human bocavirus infection in children with respiratory tract disease. Pediatr Infect Dis J. 2008; 27 969-973
- 5 Bronner U, Divis P C, Färnert A, Singh B. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malar J. 2009; 8 15
- 6 Brookes R H, Hill P C, Owiafe P K. et al . Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS ONE. 2008; 3 e2921
- 7 Cada D J, Levien T, Mistry B, Baker D E. Doripenem for Injection. Hospital Pharamacy. 2008; 43 210-221
- 8 Ceesay S J, Casals-Pascual C, Erskine J, etval. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet. 2008; 372 1545-1554
- 9 Centers for Disease Control and Prevention (CDC) . Simian malaria in a U.S. traveler – New York, 2008. MMWR Morb Mortal Wkly Rep. 2009; 58 229-232
- 10 Conde M B, Efron A, Loredo C. et al . Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009; 373 1183-1189
- 11 Crum-Cianflone N, Eberly L, Zhang Y. et al . Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985 – 2007. Clin Infect Dis. 2009; 48 1285-1292
- 12 Delgado S, Erickson B R, Agudo R. et al . Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008; 4 e1000047
- 13 Dharan N J, Gubareva L V, Meyer J J. et al . Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009; 301 1034-1041
- 14 Dryden M, O’Hare O, Sidarous E. et al .Clinical efficacy of iclaprim in complicated skin and skin structure infection: preliminary results from the ASSIST-2 clinical trial ECCMID 2008 P545.
- 15 Gorse G J, O’Connor T Z, Hall S L. et al . Human Coronavirus and Acute Respiratory Illness in Older Adults with Chronic Obstructive Pulmonary Disease. J Infect Dis. 2009; 199 847-857
- 16 Hütter G, Nowak D, Mossner M. et al . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360 692-698
- 17 Jones T. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection. Curr Opin Mol Ther. 2009; 11 90-96
- 18 Kantele A, Marti H, Felger I. et al . Monkey malaria in a European traveler returning from Malaysia. Emerg Infect Dis. 2008; 14 1434-1436
- 19 Karim S A, Coletti A, Richardson B. et al .Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5 % PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial. Paper 48LB, presented at the 16th Conference on Retroviruses and Opportunistic Infections, Montréal, Canada,. February 8 – 11, 2009
- 20 Kitahata M M, Gange S J, Abraham A G. et al . Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. N Engl J Med. 2009 Apr 1. [Epub ahead of print];
- 21 Kuijper E J, Barbut F, Brazier J S. et al . Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008; 13 31
- 22 Lee K S, Cox-Singh J, Brooke G. et al . Plasmodium knowlesi from archival blood films: Further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo. Int J Parasitol. 2009 Apr 7. [Epub ahead of print];
- 23 Leroy E M, Epelboin A, Mondonge V. et al . Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. 2009 Mar 26. [Epub ahead of print];
- 24 Li W C, Shih S R, Huang Y C. et al . Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol. 2008; 42 45-51
- 25 McGready R, Tan S O, Ashley E A. et al . A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 2008; 5 e253
- 26 Miranda I B, Weber C, Fleischmann E. et al . Validity of malaria diagnosis in nonimmune travelers in endemic areas. J Travel Med. 2008; 15 426-431
- 27 Mwanziva C, Shekalaghe S, Ndaro A, Mengerink B, Megiroo S, Mosha F, Sauerwein R, Drakeley C, Gosling R, Bousema T. Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria. Malar J. 2008; 7 232
- 28 Nicholson S C, Strauss R S, Michiels B, Noel G J. Efficacy of ceftobiprole compared to ceftriaxone +/- linezolid for the treatment of subjects hospitalized with community-acquired pneumonia. C-16. Toronto, Canada; ATS International Conference May 2008
- 29 Nicholson S C, Strauss R S, Michiels B, Noel G J. Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with community-acquired pneumonia. C-17. Toronto, Canada; ATS International Conference May 2008
- 30 Noel G J, Bush K, Bagchi P. et al . A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008; 46 647-655
- 31 Noel G J, Strauss R S, Shah A, Bagchi P. BAP00248/307 Study Group .Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Abstract K-486. ICAAC 2008
- 32 Noedl H, Se Y, Schaecher K, Smith B L. et al . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359 2619-2620
- 33 O’Meara W P, Bejon P, Mwangi T W. et al . Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet. 2008; 372 1555-1562
- 34 Palacios G, Druce J, Du L. et al . A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008; 358 991-998
- 35 Pappas P G, Kauffman C A, Andes D. et al . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48 503-535
- 36 Pass R F, Zhang C, Evans A. et al . Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009; 360 1191-1199
- 37 Robert Koch-Institut . Schwer verlaufende Infektionen mit Clostridium difficile: Zur Meldepflicht. Epid Bull. 2007; 46 424
- 38 Robert Koch-Institut . Schwer verlaufende Clostridium-difficile-assoziierte Durchfallerkrankungen. Epid Bull. 2008; 50 4
- 39 Robert Koch-Institut . Kuhpocken: Zu einer Häufung von Infektionen nach Kontakt zu „Schmuseratten” im Großraum München. Epid Bull. 2009; 6 53-56
- 40 Robert Koch-Institut . Influenza-B-assoziierte Myositis: Zu einem bundesweiten Ausbruch 2007/2008. Epid Bull. 2009; 7 61-65
- 41 Rustomjee R, Lienhardt C, Kanyok T. et al . A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008; 12 128-138
- 42 Sabin C A, Phillips A N. Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?. Curr Opin Infect Dis. 2009; 22 191-197
- 43 Scott D, Ruckle J, Dar M. et al . Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int. 2008; 50 295-299
- 44 Siegfried N, Muller M, Deeks J J, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev. 2009; 2 , CD003362
- 45 Snape M D, Perrett K P, Ford K J. et al . Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008; 299 173-184
- 46 Talbot H K, Crowe jr J E, Edwards K M. et al . Coronavirus infection and hospitalizations for acute respiratory illness in young children. J Med Virol. 2009; 81 853-856
- 47 Tobian A A, Serwadda D, Quinn T C. et al . Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009; 360 1298-1309
- 48 Van Damme L, Govinden R, Mirembe F M. et al . Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008; 359 463-472
- 49 von Reyn C F, Arbeit R D, Mtei L. et al . The DarDar prime-boost Tb vaccine trial in HIV infection: final results. PS-81689 – 20, presented at the 39th World Conference on Lung Health, Paris 2008. Int J Tubercul Lung Dis. 2008; 12 S318
- 50 When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373 1352-1363
- 51 Wolthers K C, Benschop K S, Schinkel J. et al . Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis. 2008; 47 358-363
- 52 Zeller H, Leitmeyer K, Santos C V, Coulombier D. Unknown disease in South Africa identified as arenavirus infection. Euro Surveill. 2008; 13. pii 19008
Prof. Dr. med. Thomas Löscher
Abteilung für Infektions- und Tropenmedizin, Klinikum
der Ludwig-Maximilians-Universität München
Leopoldstrasse
5
80802 München
Phone: 089/21803517
Email: loescher@lrz.uni-muenchen.de